HDAC9 and myocardial infarction: Finally, it resulted in a lasting protective impact on the heart and no toxic effects on the heart.249–251 Therefore, HDAC inhibitor SAHA is expected to be tested in clinical trials in order to better serve as a potential treatment drug for myocardial infarction in future.